Phase 1 study of lenzilumab, a recombinant anti-human GM-CSF antibody, for chronic myelomonocytic leukemia

MeSH terms

• Aged
• Aged, 80 and over
• Antibodies, Monoclonal / administration & dosage
• Antibodies, Monoclonal / adverse effects
• Antibodies, Monoclonal / pharmacokinetics
• Antibodies, Monoclonal, Humanized / administration & dosage*
• Antibodies, Monoclonal, Humanized / adverse effects
• Antibodies, Monoclonal, Humanized / pharmacokinetics*
• Antineoplastic Agents, Immunological / administration & dosage*
• Antineoplastic Agents, Immunological / adverse effects
• Antineoplastic Agents, Immunological / pharmacokinetics
• Chemotherapy, Adjuvant
• Dose-Response Relationship, Drug
• Drug-Related Side Effects and Adverse Reactions / blood
• Drug-Related Side Effects and Adverse Reactions / immunology
• Female
• Granulocyte-Macrophage Colony-Stimulating Factor / immunology
• Humans
• Leukemia, Myelomonocytic, Chronic / drug therapy*
• Leukemia, Myelomonocytic, Chronic / metabolism
• Leukemia, Myelomonocytic, Chronic / therapy
• Male
• Maximum Tolerated Dose
• Middle Aged
• Recombinant Proteins / administration & dosage
• Recombinant Proteins / adverse effects
• Recombinant Proteins / pharmacokinetics
• Treatment Outcome